Markets soar on upbeat earnings


Upbeat earnings sent the markets soaring to a sharply higher open with the Dow jumping 231 points to 20,995. Nasdaq climbed 36 points to 6,020.

On the upside

Catabasis Pharmaceuticals (Nasdaq: CATB) announced favorable results across multiple functional assessments in the MoveDMD trial for edasalonexent to treat Duchenne muscular dystrophy.

Supervalu (NYSE: SVU) reported sharply higher fourth quarter earnings that topped analyst estimates.

Capricorn Therapeutics (Nasdaq: CAPR) announced positive six month safety and efficacy results from a randomized Phase I/II HOPE clinical trial of CAP-1002 to treat Duchenne muscular dystrophy.

On the downside

Express Scripts (Nasdaq: ESRX) said that its largest client, Anthem, will not renew its contract when it expires at the end of 2019.

First quarter earnings for Barrick Gold (NYSE: ABX) fell short of expectations prompting the world's largest gold miner to cut its output outlook for its gold mine in Argentina.


ContraVir Pharmaceuticals (Nasdaq: CTRV) priced its public offering at the discounted price of $1.00 per unit.

In the broad market, advancing issues outpaced decliners by a margin of nearly 7 to 2 on the NYSE and by more than 4 to 1 on Nasdaq. The broader S&P 500 index climbed 14 points to 2,388. Bitcoin gained $14 to $1262.

About this Entry

This page contains a single entry by published on April 25, 2017 6:45 AM.

Macron's first round victory boosts markets was the previous entry in this blog.

Tariffs to be imposed on Canadian lumber is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12